Soterix Medical

Executive Summary

Soterix Medical is a privately held, US-based medical device company specializing in non-invasive neuromodulation and integrated brain monitoring technologies. Founded in 2008, the company has established itself as a world leader in transcranial electrical stimulation (tES) and transcranial magnetic stimulation (TMS) systems, offering advanced hardware and software solutions for both clinical research and therapeutic applications. With a focus on precision neuromodulation, Soterix Medical's platforms enable targeted brain stimulation while simultaneously monitoring neural activity, providing a comprehensive approach to treating neurological and psychiatric disorders. As a pre-clinical stage company, Soterix Medical continues to innovate in the neuromodulation space, positioning itself for potential regulatory milestones and commercial partnerships that could unlock significant value. The company's robust intellectual property portfolio and established presence in the research community suggest strong foundational technology, though the transition from research tools to approved therapeutics remains a key risk and opportunity.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance or CE Mark for Next-Generation Closed-Loop Neuromodulation Device45% success
• H1 2027Strategic Partnership or Licensing Agreement with Major Pharmaceutical or Medical Device Company55% success
• Q3 2026Publication of Positive Phase 2 Clinical Trial Data for Depression or Pain Indication50% success